Targeting Lung-Derived Proteins as a Therapeutic Strategy Against Breast Cancer Metastasis
Abstract
14. ABSTRACTTherapy for lung metastasis is often given systemically, causing significant toxicity. However, the lung holds potential for directtargeting via inhaled drugs; an approach that has shown promise in treating respiratory diseases but remains underexplored inoncology. This project is testing the hypothesis that CD44-interacting proteins produced in the lung promote breast cancermetastasis and can be targeted directly using inhalable drug delivery. To date, the major findings for the project are that theCD44-interacting proteins OPN, FGF2, and E/P/L selectins have complementary and important roles in mediating breastcancer metastatic behavior in response to the lung microenvironment. OPN and selectins (but not FGF2) were found to benecessary for metastatic colonization of the lung, particularly for more aggressive breast cancer cell lines. The pan-selectinantagonist bimosiamose has been selected for further study and subjected to drug formulation, optimization and qualityassurance into an inhalable inhibitor. Due to COVID19-related research shutdowns experienced between March-July 2020, a12-month no cost extension was requested and granted. Research activities have now resumed, with in vivo pre-clinicaltherapeutic studies initiated and planned for completion by the end of the final year of the award.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1118290
Entities
People
- Alison Allan
- Raimar Loebenberg
Organizations
- Western University